ArticleFrontiers in oncology2026
Clinical response to FGFR inhibitors in patients with FGFR2-amplified advanced gastric cancer: two case reports.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with gastric cancer (GC) harboring fibroblast growth factor receptor 2 (FGFR2) amplification showed significantly worse survival, compared with patients with FGFR2-unamplified GC. Although various targeted drugs have been developed, previous studies have shown that their efficacy remains suboptimal in most patients within this subgroup. We retrospectively present two cases of FGFR2-amplified advanced GC treated with FGFR inhibitors. Case 1 was a 52-year-old female diagnosed with stage IVB (cTxN+M1, bone and lymph node metastases, HER2-negative, CPS = 2) poorly differentiated signet-ring cell carcinoma, harboring high-level FGFR2 amplification (gene copy number=24.7). Due to extensive bone metastases resulting in severe anemia, pain, and limited mobility (performance status 3), the patient was intolerant to chemotherapy and immunotherapy. In the first-line setting, she received pemigatinib, achieving a progression-free survival (PFS) of 4.4 months and an overall survival (OS) of 8.3 months, accompanied by a significant decrease in tumor markers and rapid clinical symptom improvement. Case 2 was a 61-year-old female diagnosed with stage IVB (cT4bN+M1, liver and lymph node metastases, HER2-negative, CPS = 5) poorly differentiated adenocarcinoma. In the third-line setting, she received infigratinib, attaining a PFS of 5.7 months and an OS of 18.5 months. Both patients experienced predictable and manageable FGFR inhibitor-related adverse events (e.g., keratitis, onychotoxicity, hyperphosphatemia). This case series offers hypothesis-generating observations suggesting potential activity of FGFR inhibitors (such as pemigatinib and infigratinib) in patients with FGFR2-amplified advanced gastric cancer who have limited conventional therapeutic options or are intolerant to chemotherapy, highlighting the importance of next-generation sequencing-guided precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.